Production of Anti-c-Myc Monoclonal Antibody Inhibiting DNA Binding of c-Myc and Max Dimer by Epitope Peptide–CpG-DNA–Liposome Complex Without Carriers

International Journal of Peptide Research and Therapeutics

Volumn 25, Issue 1, 2019, Pages 75-82

  Park, Byoung Kwon ^a   Gautam, Avishekh ^a   Maharjan, Sony ^a   Lee, Su In ^a   Lee, Younghee ^b   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

B cell epitope; C Myc; MAb; Max

Indexed keywords

ARGINYLSERYLPHENYLALANYLPHENYLALANYLALANYLLEUCYLARGINYLASPARTYLGLUTAMINYLISOLEUCYLPROLYLGLUTAMYLLEUCYLGLUTAMYLASPARAGINYLASPARAGINYLGLUTAMYLLYSYLALANYLPROLYLLYSYLVALYLVALYLISOLEUCYLLEUCINE; IMMUNOGLOBULIN G2A ANTIBODY; LIPOSOME; MAX PROTEIN; MYC PROTEIN; PEPTIDES AND PROTEINS; SERYLSERYLASPARTYLTHREONYLGLUTAMYLGLUTAMYLASPARAGINYLVALYLLYSYLARGINYLARGINYLTHREONYLHISTIDINYLASPARAGINYLVALYLLEUCYLGLUTAMYLARGINYLGLUTAMINYLARGINYLARGINYLASPARAGINYLGLUTAMYLLEUCYLLYSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PREDICTION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 85034270744     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-017-9649-6     Document Type: Article

References (33)

1. Avignolo C, Bagnasco L, Biasotti B et al (2008) Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 22(4):1237–1245
2. Berg T (2011) Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol 348:139–149
3. Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251(4998):1211–1217
4. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121–1124
5. Conacci-Sorrell M, McFerrin L, Eisenman RN (2014) An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4(1):a014357
6. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19(1):1–11
7. Dang CV (2012) MYC on the path to cancer. Cell 149(1):22–35
8. Guillard S, Minter RR, Jackson RH (2015) Engineering therapeutic proteins for cell entry: the natural approach. Trends Biotechnol 33(3):163–171
9. Hönnemann J, Sanz-Moreno A, Wolf E, Eilers M, Elsässer HP (2012) Miz1 is a critical repressor of cdkn1a during skin tumorigenesis. PLoS ONE 7(4):e34885
10. Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV (2015) MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43:11–21
11. Kiessling A, Sperl B, Hollis A, Eick D, Berg T (2006) Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 13(7):745–751
12. Kim D, Kwon S, Rhee JW et al (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12:29
13. Kwon S, Choi KC, Kim YE et al (2014) Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res 74(14):3844–3856
14. Marschall AL, Zhang C, Frenzel A et al (2014) Delivery of antibodies to the cytosol: debunking the myths. MAbs 6(4):943–956
15. Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193–205
16. Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: marvelously complex. Adv Cancer Res 84:81–154
17. Park BK, Choi SH, Kim YE et al (2015) Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34(2):101–109
18. Park BK, Lee SI, Lee Y et al (2016) Effect of a monoclonal antibody against relaxin-2 on cancer cell growth inhibition. Appl Biol Chem 59(5):739–746
19. Posternak V, Cole MD (2016) Strategically targeting MYC in cancer. F1000Res. 10.12688/f1000research.7879.1.eCollection2016
20. Prochownik EV, Vogt PK (2010) Therapeutic targeting of Myc. Genes Cancer 1(6):650–659
21. Sakamuro D, Prendergast GC (1999) New Myc-interacting proteins: a second Myc network emerges. Oncogene 18(19):2942–2954
22. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287
23. Sheiness D, Bishop JM (1979) DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 31(2):514–521
24. Sohn WJ, Kim D, Lee KW et al (2007) Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol Immunol 44(13):3273–3282
25. Soucek L, Jucker R, Panacchia L et al (2002) Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62(12):3507–3510
26. Stellas D, Szabolcs M, Koul S et al (2014) Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst 106(12). 10.1093/jnci/dju320
27. Varmus HE (1984) The molecular genetics of cellular oncogenes. Annu Rev Genet 18:553–612
28. Vogt PK (2012) Retroviral oncogenes: a historical primer. Nat Rev Cancer 12(9):639–648
29. Wang H, Hammoudeh DI, Follis AV et al (2007) Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 6(9):2399–2408
30. Wang J, Ma X, Jones HM et al (2014) Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. J Transl Med 12:226
31. Wiese KE, Walz S, von Eyss B et al (2013) The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 3(12):a014290
32. Yokoyama WM, Christensen M, Santos GD, Miller D (2006) Production of monoclonal antibodies. Curr Protoc Immunol. 10.1002/0471142735.im0205s74
33. Zhang W, Kater AP, Widhopf GF 2nd et al (2010) B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 107(44):18956–18960